Integra LifeSciences Holdings Corporation (IART)
Integra LifeSciences Holdings Corporation (IART) Q3 2024 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q3 2024 Earnings Call Transcript November 4, 2024 8:30 AM ET Company Participants Chris Ward - IR Stuart Essig - Executive Chairman Jan De Witte - President and CEO Lea Knight - CFO Conference Call Participants Steven Lichtman - Oppenheimer Vik Chopra - Wells Fargo Ryan Zimmerman - BTIG Kristen Stewart - C.L. King Robbie Marcus - JPMorgan Matt Taylor - Jefferies Richard Newitter - Truist Securities Craig Bijou - Bank of America Securities Joanne Wuensch - Citi Chris Ward Good morning and thank you for joining the Integra LifeSciences Third Quarter 2024 Earnings Conference Call.
Integra (IART) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra LifeSciences (IART) Beats Q3 Earnings and Revenue Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.76 per share a year ago.
Here's Why You Should Hold IART Stock in Your Portfolio Now
Integra's strong growth in the Tissue Technologies and CSS business segment bolsters investors' confidence in the stock.
Integra's (IART) Q2 Earnings and Revenues Top, Margins Down
Integra's (IART) second-quarter 2024 results reflect strong demand for its diverse portfolio of leading brands and the continued successful market adoption of CereLink.
Integra LifeSciences Analysts Cut Their Forecasts After Q2 Results
Integra LifeSciences IART reported upbeat second-quarter earnings and lowered its FY24 guidance below estimates on Monday.
Why Integra Lifesciences Stock Is Sinking Today
Integra Lifesciences topped analysts' Q2 revenue and earnings estimates. However, the company reduced its full-year guidance.
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra LifeSciences (IART) Q2 Earnings and Revenues Surpass Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.71 per share a year ago.
Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra's (IART) New Site to Produce Recalled Tissue Products
Integra (IART) is set to recommence the manufacturing of PriMatrix and SurgiMend at its new facility in Braintree, MA.
Why Is Integra (IART) Up 26% Since Last Earnings Report?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
